Clinical Trial Update: S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial update of temozolomide in patients with unresectable or metastatic gastrointestinal stromal tumors (S9926) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Temodar (temozolomide) (temozolomide)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Gastrointestinal Stromal Tumor | Phase 2 | Status: COMPLETED